Sugi Predict

Sugi Predict / Compounds / SCHEMBL7183284

SCHEMBL7183284

SCHEMBL7183284

COc1cc(OC)c(C(=O)[PH](=O)c2c(Cl)cc(C(=O)c3ccccc3)c(Cl)c2OC)c(OC)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ KMT2A Q03164 1/20 0.40
▸ LMNA P02545 3/20 0.39
▸ MAPK1 P28482 3/20 0.39
▸ HTT P42858 3/20 0.39
▸ HPGD P15428 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ CYP2C19 P33261 2/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ PGR P06401 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ SLC6A2 P23975 1/20 0.39
▸ PDE4A P27815 1/20 0.39
▸ HRH1 P35367 1/20 0.39
▸ SLC6A3 Q01959 1/20 0.39
▸ PDE4D Q08499 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180926 0.92 MAPT (0.42) MAPTSMN1; SMN2KMT2ALMNAMAPK1
SCHEMBL7186628 0.92 MAPT (0.41) MAPTSMN1; SMN2KMT2ALMNAMAPK1
SCHEMBL7174594 0.88 ABCG2 (0.40) MAPTSMN1; SMN2KMT2ALMNAMAPK1
SCHEMBL7181182 0.88 TUBB4A (0.39) MAPTSMN1; SMN2KMT2ALMNAMAPK1
SCHEMBL7187673 0.87 KMT2A (0.40) MAPTKMT2ALMNAMAPK1HTT
SCHEMBL7184058 0.87 MAPT (0.41) MAPTSMN1; SMN2KMT2ALMNAMAPK1
SCHEMBL7175461 0.86 MAPT (0.45) MAPTSMN1; SMN2KMT2ALMNAMAPK1
SCHEMBL7183278 0.85 MAPT (0.38) MAPTKMT2ALMNAMAPK1HTT
SCHEMBL7189545 0.84 KMT2A (0.36) MAPTKMT2ALMNAMAPK1HTT
SCHEMBL7188161 0.84 MAPT (0.43) MAPTSMN1; SMN2KMT2ALMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885SMN1; SMN2 2939/4885KMT2A 1586/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPT 4859/4885SMN1; SMN2 3105/4885KMT2A 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.